Ali M.A. Al-Kufaishi, Lamia A. M. Al-Mashhedy, Bushra Jaber Al-Rubaie
Kuh.firstname.lastname@example.org , email@example.com , firstname.lastname@example.org
Ali M.A. Al-Kufaishi1, Lamia A. M. Al-Mashhedy2, Bushra Jaber Al-Rubaie3
1Al-Furat Al-Awsat Technical University College of Health and Medical Techniques, Department of Medical Laboratory Techniques, Kufa, Iraq 31003.
2University of Babylon, College of Science, Chemistry Department.
3University of Babylon, College of Medicine, Gynecology Department.
Volume - 13,
Issue - 9,
Year - 2020
HIGH LIGHTS: HPV16 and related to cervical cancer; Oxidative stress that associated with HPV16 or anther microorganism that infected cervical; A modified method of lipids peroxidation uses a good marker to assessment the redox status. Objective: Application of modified methods to assessment of lipids peroxidation in patients with chronic cervicitis. Design and Methods: A comparative study to the estimation of lipids peroxidation of the patients with HPV16 through divided the cases into three groups, healthy women (G1), chronic cervicitis patients without HPV16 (G2) and chronic cervicitis patients with HPV16 (G3). Results: The results show the high levels of lipids peroxidation in the patients (51.89) for cervical mucus and (22.59) for a serum with HPV 16, where (37.51) in cervical mucus and (19) for serum in the patients without HPV 16, compared with healthy (6.95) in serum and (25.54) in cervical mucus. Conclusion: HPV 16 consist of more than 50% from cervical cancer, but is alone not enough to develop cancer, there are supplement agents such as raise of reactive oxygen species and reduction of antioxidants. The higher levels of lipids peroxidation in the serum and mucus of the patients compared with control. So, lipids peroxidation is a good biomarker to evaluate the redox status in the patients compared with control.
Cite this article:
Ali M.A. Al-Kufaishi, Lamia A. M. Al-Mashhedy, Bushra Jaber Al-Rubaie. A Modified Method to Determine Lipids Peroxidation in patients with HPV16 Cervicitis. Research J. Pharm. and Tech 2020; 13(9):4087-4091. doi: 10.5958/0974-360X.2020.00722.2
1. H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radic. Biol. Med., vol. 11, no. 1, pp. 81–128, 1991.
2. T. L. Dormandy and D. G. Wickens, “The experimental and clinical pathology of diene conjugation,” Chem. Phys. Lipids, vol. 45, no. 2–4, pp. 353–364, 1987.
3. J. D. Morrow et al., “Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers—smoking as a cause of oxidative damage,” N. Engl. J. Med., vol. 332, no. 18, pp. 1198–1203, 1995.
4. E. R. Rosenblum, J. S. Gavaler, and D. H. Van Thiel, “Lipid peroxidation: a mechanism for alcohol-induced testicular injury,” Free Radic. Biol. Med., vol. 7, no. 5, pp. 569–577, 1989.
5. L. K. Dahle, E. G. Hill, and R. T. Holman, “The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters,” Arch. Biochem. Biophys., vol. 98, no. 2, pp. 253–261, 1962.
6. C. K. Sen, L. Packer, and O. Hänninen, “Oxidative stress indices: analytical aspects and significance,” Handb. Oxid. antioxidants Exerc., p. 433, 2000.
7. B. Gillham, D. K. Papachristodoulou, and J. H. Thomas, “Free radicals in health and disease,” Wills Biochem. Basis Med. 3rd ed. Oxford Butterworth Heinemann, pp. 353–369, 1997.
8. R. P. Bird, S. S. O. Hung, M. Hadley, and H. H. Draper, “Determination of malonaldehyde in biological materials by high-pressure liquid chromatography,” Anal. Biochem., vol. 128, no. 1, pp. 240–244, 1983.
9. T. Ichinose, M. G. Miller, and T. Shibamoto, “Gas chromatographic analysis of free and bound malonaldehyde in rat liver homogenates,” Lipids, vol. 24, no. 10, pp. 895–898, 1989.
10. S. Jablonska, L. Fabjanska, and I. Formas, “On the viral etiology of epidermodysplasia verruciformis,” Dermatology, vol. 132, no. 5, pp. 369–385, 1966.
11. F. Pass, M. Reissig, K. V Shah, M. Eisinger, and G. Orth, “Identification of an immunologically distinct papillomavirus from lesions of epidermodysplasia verruciformis,” J. Natl. Cancer Inst., vol. 59, no. 4, pp. 1107–1112, 1977.
12. H. Pfister, F. Nürnberger, L. Gissmann, and H. Zur Hausen, “Characterization of a human papillomavirus from epidermodysplasia verruciformis lesions of a patient from upper‐volta,” Int. J. Cancer, vol. 27, no. 5, pp. 645–650, 1981.
13. R. Zhou, C. Wei, J. Liu, Y. Luo, and W. Tang, “The prognostic value of p53 expression for patients with cervical cancer: a meta analysis,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 195, pp. 210–213, 2015.
14. J. Pontén et al., “Strategies for global control of cervical cancer,” Int. J. cancer, vol. 60, no. 1, pp. 1–26, 1995.
15. E. J. Shillitoe, “Papillomaviruses as targets for cancer gene therapy,” Cancer Gene Ther., vol. 13, no. 5, p. 445, 2006.
16. A. J. Levine, “p53, the cellular gatekeeper for growth and division,” Cell, vol. 88, no. 3, pp. 323–331, 1997.
17. H. R. Mcmurray, D. Nguyen, T. F. Westbrook, and D. J. McAnce, “Biology of human papillomaviruses,” Int. J. Exp. Pathol., vol. 82, no. 1, pp. 15–33, 2001.
18. A. A. Okunowo et al., “Women’s knowledge of cervical cancer and uptake of Pap smear testing and the factors influencing it in a Nigerian tertiary hospital,” J. Cancer Res. Pract., vol. 5, no. 3, pp. 105–111, 2018.
19. R. Xu et al., “Effects of topical PaiTeLing in nude mice implanted with human condyloma acuminatum tissue infected with HPV 6, 31, and 81: comparison with imiquimod and interferon-α-2b,” bioRxiv, p. 563536, 2019.
20. P. E. Gravitt et al., “Improved amplification of genital human papillomaviruses,” J. Clin. Microbiol., vol. 38, no. 1, pp. 357–361, 2000.
21. Y. B. Pandey, N., Chaurasia, J., Tiwari, O. and Tripathi, “Antioxidant properties of different fractions of tubers from Pueraria tuberosa Linn,” Food Chem., vol. 105, pp. 219–222, 2007.